GlassScriptPhysician profile
Vaishali Cooper
NPI 1730548058
$16,681.02
in general payments reported to CMS, 2019-2025
36 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,306 · 2022: $4,708 · 2023: $4,272 · 2024: $2,350 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,666.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,686.42 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,726.68 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $1,593.75 | 2021-2025 | Aristada, Vivitrol, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,332.28 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,174.40 | 2021-2024 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,120.93 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Axsome Therapeutics, INC. | $1,098.54 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $833.15 | 2021-2024 | Rexulti |
| Jazz Pharmaceuticals INC. | $636.07 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $530.40 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $485.35 | 2021-2024 | Trintellix |
| Corium, LLC | $477.94 | 2021-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $409.04 | 2021-2024 | Qelbree, Qelbree |
| Bausch Health US, LLC | $343.20 | 2021-2024 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $229.27 | 2022-2024 | Quviviq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $229.17 | 2021-2023 | Sublocade |
| Ironshore Pharmaceuticals INC. | $218.61 | 2022-2023 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $195.42 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $187.52 | 2021-2024 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $184.03 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $147.92 | 2021-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $123.75 | 2024 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $117.52 | 2022 | |
| Tris Pharma INC | $95.40 | 2022-2024 | Dyanavel Xr |
| Livanova USA, INC. | $78.83 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Uswm, LLC | $68.94 | 2021 | |
| Collegium Pharmaceutical, INC. | $65.59 | 2023 | Belbuca, Xtampza |
| Adlon Therapeutics L.P. | $65.40 | 2021 | |
| Amgen INC. | $65.39 | 2022 | |
| Grt US Holding, INC. | $38.99 | 2022 | |
| Brainsway USA INC | $34.60 | 2021-2022 | |
| Almatica Pharma LLC | $22.68 | 2022 | |
| Sage Therapeutics, LLC | $21.57 | 2022 | |
| Scilex Pharmaceuticals INC. | $15.30 | 2022 | |
| Aytu Biopharma, INC. | $13.98 | 2021 | |
| Avion Pharmaceuticals | $12.99 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vaishali Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.